Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.

Wickström, Anne; Dahle, Charlotte; Vrethem, Magnus; Svenningsson, Anders

Wickström, Anne; Dahle, Charlotte; Vrethem, Magnus; Svenningsson, Anders.

Affiliation

Wickström A; Department of Pharmacology and Clinical Neuroscience, Section of Neuroscience, Umeå University, Sweden.
Dahle C; Department of Clinical and Experimental Medicine, Clinical Immunology, Faculty of Health Sciences, Linköping University, Sweden Clinical Immunology and Transfusion Medicine, County Council of Östergötland, Sweden.
Vrethem M; Department of Clinical and Experimental Medicine, Neurology and Clinical Neurophysiology, Faculty of Health Sciences, Linköping University, Sweden Department of Neurology and Neurophysiology, County Council of Östergötland, Sweden.
Svenningsson A; Department of Pharmacology and Clinical Neuroscience, Section of Neuroscience, Umeå University, Sweden anders.svenningsson@neuro.umu.se.

Mult Scler ; 20(8): 1095-101, 2014 07.

Article in En | MEDLINE | ID: mdl-24378984

Subject(s)

Absenteeism; Immunologic Factors/therapeutic use; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Natalizumab/therapeutic use; Sick Leave; Adult; Age Factors; Exercise Tolerance/drug effects; Female; Humans; Insurance, Disability; Male; Middle Aged; Mobility Limitation; Multiple Sclerosis, Relapsing-Remitting/diagnosis; Multiple Sclerosis, Relapsing-Remitting/physiopathology; Multiple Sclerosis, Relapsing-Remitting/psychology; Muscle Fatigue/drug effects; Prospective Studies; Recovery of Function; Risk Factors; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Walking; Work Capacity Evaluation

Key words

Multiple sclerosis; biological drugs; fatigue; motor fatigue; natalizumab; walking distance; work ability

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Sick Leave / Multiple Sclerosis, Relapsing-Remitting / Absenteeism / Natalizumab / Immunologic Factors Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2014 Type: Article Affiliation country: Sweden

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google